TRINETRA › Sectors › Healthcare
Gland Pharma Limited (GLAND) — share price, P/E and fundamentals
Gland Pharma Limited (NSE: GLAND) closed at ₹3,095.90 on 30 Oct 2026, +59.8% over one year, against a 52-week range of ₹1,573.60 – ₹3,171.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 10 Aug 2026) it reported revenue of ₹1,800 cr and net profit of ₹317 cr, a 17.6% net margin; revenue grew 19.6% and profit grew 39.1% year on year.
On four consecutive filed quarters its trailing P/E is 45.2; since 20 May 2025 its own P/E has ranged from 30.0 to 49.6 (median 40.7), and today's reading is higher than 82% of those 358 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 12.2%, ROCE 16.1%, debt-to-equity 0.02, Piotroski F-score 9 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 67% of 63 sector peers; PBT margin higher than 68% of 63 sector peers; ROE higher than 44% of 63 sector peers.
Key figures
| Last close | ₹3,095.90 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +6.9% / +80.7% / +59.8% |
| 52-week low – high | ₹1,573.60 – ₹3,171.00 |
| Market capitalisation | ₹51,070 cr |
| Trailing P/E | 45.2 |
| Price / book | 4.93 |
| EV / EBITDA | 23.4 |
| Earnings yield | 2.2% |
| TTM EPS | ₹68.43 |
| TTM net profit | ₹1,129 cr |
| Quarter revenue | ₹1,800 cr |
| Quarter net profit | ₹317 cr |
| Net margin | 17.6% |
| Revenue growth (YoY) | +19.6% |
| Profit growth (YoY) | +39.1% |
| Return on equity | 12.2% |
| ROCE | 16.1% |
| Debt / equity | 0.02 |
| Current ratio | 4.68 |
| Free cash flow | ₹541 cr |
| Piotroski F-score | 9 / 9 |
| Average daily turnover (50 days) | ₹105.9 cr |
Against Healthcare peers
| Metric | GLAND | Peer median | Percentile |
|---|---|---|---|
| Net margin | 17.61 | 12.67 | 67 |
| PBT margin | 24.16 | 17.57 | 68 |
| ROE | 12.24 | 13.87 | 44 |
| ROCE | 16.12 | 17.26 | 46 |
| Debt / equity | 0.02 | 0.11 | 34 |
| Cash conversion | 1.00 | 1.25 | 32 |
| Trailing P/E | 45.24 | 43.07 | 51 |
| P/B | 4.93 | 6.02 | 39 |
Questions
What is the P/E ratio of Gland Pharma Limited?
Gland Pharma Limited's trailing P/E is 45.2, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 20 May 2025 its P/E has ranged 30.0–49.6.
What were Gland Pharma Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Gland Pharma Limited reported revenue of ₹1,800 cr and net profit of ₹317 cr (consolidated), filed with the exchange on 10 Aug 2026.
What is Gland Pharma Limited's ROE?
Return on equity is 12.2% based on the balance sheet dated 31 Mar 2026.
Does Gland Pharma Limited have debt?
Debt-to-equity is 0.02 on the balance sheet dated 31 Mar 2026.
What is GLAND's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, GLAND traded between ₹1,573.60 and ₹3,171.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.